Long-term safety study for Astegolimab in COPD
Part of Lungs & breathing clinical trials.
This study looks at how safe Astegolimab stays over the long run for people with COPD. It enrolls participants who finished a prior 52-week Astegolimab treatment study and may help confirm long-term side effects and overall safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the 52-week treatment period in the earlier parent COPD study (GB43311 or GB44332)
- You did not withdraw consent or stop the parent study early
- You did not permanently stop the study medicine during the parent study
- You did not have major missed study visits or other serious non-following of the plan in the parent study
- Since joining the parent study, you did not develop asthma
- Since joining the parent study, you did not develop a new significant lung condition besides COPD
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people with COPD who have already completed an earlier lunsekimig study. It aims to check the safety and effectiveness of the treatment over a longer period.
This trial tests whether an infusion of donor stem cells can help people with moderate to severe COPD breathe easier. If you are a current or former smoker aged 40 to 80, your symptoms are stable, and your lung function meets specific targets, you may be able to join.
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.